Guardant Health Appoints Vijaya Gadde to its Board of Directors
“We’re delighted to welcome Vijaya to our Board of Directors. Vijaya is an outstanding addition to our Board and a proven business leader who not only brings a keen public policy and regulatory perspective having dealt with complex global issues, but also has successfully steered hypergrowth technology companies during pivotal times. Her passion for our important work coupled with this experience will undoubtedly help
“I am excited to join the Guardant Health Board and am eager to contribute to the company’s inspiring mission of dramatically improving cancer care,” said
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/89814409-41e0-44d5-8267-2c0eb5d839e2
Source: Guardant Health, Inc.